Ixabepilone for the treatment of solid tumors: a review of clinical data.
BACKGROUND
Microtubule stabilizing agents such as taxanes are an integral part of therapy for multiple solid tumors. However, due to limitations of these agents, newer more effective cytotoxic agents are necessary. Ixabepilone, an epothilone B analog, is a novel microtubule stabilizing agent.


OBJECTIVE
This review provides an updated summary of emerging clinical experience with Ixabepilone.


METHODS
Phase I, II and III clinical trials presented in abstract form or journal articles found within a PubMed search through November 2007 are described in this review.


CONCLUSIONS
Ixabepilone offers promising clinical activity in a variety of solid tumors. Ixabepilone is FDA-approved for the treatment of breast cancer refractory to anthracyclines and taxanes. The optimal dose and schedule are still being defined, and the predominant side effects are bone marrow suppression and neuropathy.
Denduluri
Neelima
N
National Cancer Institute, National Institutes of Health, Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, 10 Center Drive, Room 12N226, Bethesda, Maryland 20892, USA.
Swain
Sandra M
SM
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D034261:Epothilones / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome; D050257:Tubulin Modulators / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D034261:Epothilones; D050257:Tubulin Modulators; C430592:ixabepilone